RAPS recognizes that the current situation in Ukraine impacts our members and customers on many levels. If you are directly impacted by the current situation in the region and are challenged to meet your deadlines or obligations to RAPS, please reach out to raps@raps.org so that we can defer those challenges. Your health and safety are paramount to us.

Regulatory Focus™ > News Articles > Another Reorganization for CDER: Its Office of Management

Another Reorganization for CDER: Its Office of Management

Posted 15 January 2015 | By Alexander Gaffney, RAC

Another Reorganization for CDER: Its Office of Management

The US Food and Drug Administration's Center for Drug Evaluation and Research (CDER) is already off to a busy start this year, having released new long-sought functions on its website, launched its new Office of Pharmaceutical Quality (OPQ) and hired a permanent director for its Office of Generic Drugs.

The changes, it seems, aren't stopping there. Last week, CDER also announced a reorganization of its Office of Management in the hopes of streamlining its approach to managing the nation's drug regulators.

In an email to FDA staff on 8 January 2015, CDER Director Janet Woodcock said the new management staff will include two additions: a strategic programs and initiatives staff, and an ethics liaison staff.

The overall will also see the creation of two new divisions:

  • The Division of User Fee Management and Budget Formulation (DUFMBF), which will oversee the generics branch, legal and operations branch, and the brands branch.
  • The Division of Budget Execution and Resource Management (DBERM), which will replace the Division of Management and Budget and oversee three branches: budget execution, acquisitions support and financial accountability.

A third division, the Division of Management Services (DMS), which oversees most of CDER's HR functions, will continue to exist with some minor changes. CDER also said it plans to eliminate a total of six branches:

  • Program and Resource Management Branch
  • Management Analysis Branch
  • Program and Resource Management Branch
  • Management Analysis Branch
  • Program Management Services Branch
  • Interface Management Branch

Woodcock said the reorganization will help CDER to "better meet the management services needs of a growing Center with expanding authorities" under the Food and Drug Administration Safety and Innovation Act (FDASIA) of 2012.

 

© 2022 Regulatory Affairs Professionals Society.